Blackhill Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$57.2M Buy
263,110
+16,000
+6% +$3.55M 2.95% 4
2025
Q4
$56.5M Buy
247,110
+300
+0.1% +$68.3K 2.91% 4
2025
Q3
$57.1M Sell
246,810
-6,000
-2% -$1.22M 2.83% 4
2025
Q2
$46.9M Sell
252,810
-6,000
-2% -$1.12M 2.71% 4
2025
Q1
$54.2M Hold
258,810
3.15% 4
2024
Q4
$46M Hold
258,810
2.38% 4
2024
Q3
$51.1M Sell
258,810
-10,000
-4% -$1.87M 2.94% 4
2024
Q2
$46.1M Buy
268,810
+18,400
+7% +$3.05M 2.86% 4
2024
Q1
$45.6M Sell
250,410
-250
-0.1% -$43.1K 2.62% 3
2023
Q4
$38.8M Hold
250,660
3.11% 4
2023
Q3
$37.4M Sell
250,660
-10,200
-4% -$1.5M 3.6% 4
2023
Q2
$35.1M Sell
260,860
-2,400
-0.9% -$352K 3.77% 4
2023
Q1
$42M Buy
263,260
+3,700
+1% +$566K 4.68% 4
2022
Q4
$41.9M Hold
259,560
4.86% 3
2022
Q3
$34.8M Buy
259,560
+3,400
+1% +$488K 4.14% 4
2022
Q2
$39.2M Sell
256,160
-1,600
-0.6% -$244K 4.55% 3
2022
Q1
$41.8M Buy
257,760
+6,000
+2% +$872K 3.97% 4
2021
Q4
$34.1M Hold
251,760
2.91% 6
2021
Q3
$27.2M Hold
251,760
2.35% 8
2021
Q2
$28.4M Buy
251,760
+4,200
+2% +$473K 2.58% 8
2021
Q1
$26.8M Buy
247,560
+300
+0.1% +$32.1K 2.34% 8
2020
Q4
$26.5M Hold
247,260
3.2% 7
2020
Q3
$21.7M Sell
247,260
-2,000
-0.8% -$188K 2.93% 9
2020
Q2
$24.5M Buy
249,260
+55,290
+29% +$4.87M 3.6% 7
2020
Q1
$14.8M Buy
193,970
+400
+0.2% +$34.1K 3.08% 10
2019
Q4
$17.1M Buy
193,570
+10,400
+6% +$863K 2.5% 10
2019
Q3
$13.9M Sell
183,170
-3,600
-2% -$247K 2.19% 12
2019
Q2
$13.6M Hold
186,770
2.19% 11
2019
Q1
$15.1M Buy
186,770
+9,600
+5% +$785K 2.58% 10
2018
Q4
$16.3M Sell
177,170
-3,390
-2% -$298K 3.13% 10
2018
Q3
$17.1M Sell
180,560
-200
-0.1% -$19K 2.76% 10
2018
Q2
$16.7M Sell
180,760
-11,900
-6% -$1.16M 2.98% 7
2018
Q1
$18.2M Sell
192,660
-3,000
-2% -$330K 3.4% 7
2017
Q4
$18.9M Sell
195,660
-8,000
-4% -$754K 3.41% 7
2017
Q3
$18.1M Hold
203,660
3.4% 8
2017
Q2
$14.8M Hold
203,660
2.83% 8
2017
Q1
$13.3M Sell
203,660
-3,500
-2% -$220K 2.45% 10
2016
Q4
$13M Sell
207,160
-10,000
-5% -$610K 2.46% 8
2016
Q3
$13.7M Sell
217,160
-8,000
-4% -$518K 2.28% 9
2016
Q2
$13.9M Hold
225,160
2.26% 10
2016
Q1
$12.9M Sell
225,160
-30,000
-12% -$1.67M 2.11% 10
2015
Q4
$15.1M Hold
255,160
2.35% 9
2015
Q3
$13.9M Sell
255,160
-400
-0.2% -$26K 1.87% 10
2015
Q2
$17.2M Hold
255,560
2.07% 8
2015
Q1
$15M Sell
255,560
-1,400
-0.5% -$84.6K 1.82% 11
2014
Q4
$16.8M Hold
256,960
2.1% 9
2014
Q3
$14.8M Hold
256,960
2.02% 10
2014
Q2
$14.5M Sell
256,960
-3,800
-1% -$199K 1.97% 8
2014
Q1
$13.4M Sell
260,760
-6,000
-2% -$303K 1.93% 9
2013
Q4
$14.1M Sell
266,760
-1,900
-0.7% -$93.4K 2.14% 9
2013
Q3
$12M Hold
268,660
1.93% 9
2013
Q2
$11.1M Buy
+268,660
New +$11.7M 1.8% 10

Other funds holding ABBV

Blackhill Capital's ABBV Position: Q1 2026 in Review

Blackhill Capital increased its AbbVie (ABBV) stake by 6.5% in Q1 2026, buying an estimated $3.55M and bringing the position to 263,110 shares worth $57.2M. The position accounts for 2.95% of the portfolio, ranked #4.

Blackhill Capital first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Blackhill Capital held 263,110 shares of AbbVie worth $57.2M as of Q1 2026.
  • Blackhill Capital bought 16,000 AbbVie shares in Q1 2026, an estimated $3.55M.
  • AbbVie made up 2.95% of Blackhill Capital's portfolio in Q1 2026, its #4 holding.
  • Blackhill Capital first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Blackhill Capital's 13F filing for Q1 2026, filed 14 May 2026.